Clarithromycin (DB01211): A Comprehensive Pharmacological and Clinical Monograph

1.0 Executive Summary & Drug Profile

1.1 Overview of Clarithromycin: A Second-Generation Macrolide

Clarithromycin is a semi-synthetic, second-generation macrolide antibiotic belonging to the polyketide class of natural products.[1] Developed in 1980 and first approved for medical use in 1990, it is derived from erythromycin A through the methylation of the hydroxyl group at the C-6 position of the 14-membered lactone ring.[2] This specific structural modification was engineered to overcome key limitations of its parent compound, erythromycin. The primary advantages conferred by this change are enhanced stability in acidic environments, which significantly reduces the incidence of gastrointestinal side effects, and a more favorable pharmacokinetic profile, including improved oral absorption and a longer half-life.[5]

As a small molecule drug, clarithromycin has become a cornerstone in the treatment of a wide array of common bacterial infections.[1] It is widely prescribed for infections of the upper and lower respiratory tract, skin and soft tissues, and for the eradication of

Helicobacter pylori in peptic ulcer disease.[1] Its clinical utility is further extended to the management of opportunistic infections in immunocompromised individuals, most notably for the treatment and prophylaxis of disseminated

Mycobacterium avium complex (MAC) infection.[2]

Beyond its well-established antibacterial functions, clarithromycin exhibits significant immunomodulatory and anti-inflammatory properties that are independent of its antimicrobial activity.[5] These effects, which include the modulation of cytokine production, have positioned the drug as a subject of intensive research for potential applications in chronic inflammatory diseases and even as an adjunct in oncology.[10] More recently, an entirely distinct mechanism involving negative allosteric modulation of the GABA-A receptor has been identified, leading to its investigation as a novel therapy for central nervous system disorders of hypersomnolence.[7]

Despite its therapeutic versatility, the clinical use of clarithromycin is significantly constrained by two major factors. First, it is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system, which results in a high potential for numerous and often severe drug-drug interactions.[6] Second, a notable cardiovascular safety concern has emerged, linking its use in patients with heart disease to an increased long-term risk of mortality.[7] These characteristics create a complex risk-benefit profile that requires careful clinical consideration.

1.2 Key Identifiers and Physicochemical Properties

Clarithromycin is chemically known as 6-O-methylerythromycin.[2] It presents as a white or almost white crystalline powder, though it can form colorless needles when crystallized from specific solvents like chloroform and diisopropyl ether.[2] The compound is practically insoluble in water but demonstrates solubility in organic solvents such as acetone and methylene chloride, and is slightly soluble in methanol, ethanol, and acetonitrile.[4] Its fundamental identifiers and properties are consolidated in Table 1 for reference.

Table 1: Key Identifiers and Physicochemical Properties of Clarithromycin

Identifier Type	Value	Source(s)
Generic Name	Clarithromycin	1
English Name	Clarithromycin	1
DrugBank ID	DB01211	1
CAS Number	81103-11-9	2
Type	Small Molecule	1
Molecular Formula	C38​H69​NO13​	19
Molecular Weight (Average)	747.95 g/mol	2
Molecular Weight (Monoisotopic)	747.47689126 Da	2
PubChem CID	84029	2
ChEMBL ID	CHEMBL1741	2
UNII	H1250JIK0A	2
IUPAC Name	(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-oxy-14-ethyl-12,13-dihydroxy-4-oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione	2

1.3 Regulatory and Development History

Clarithromycin was developed in 1980 by the Japanese pharmaceutical company Taisho Pharmaceutical and was first approved for medical use in 1990.[6] Its development represents a significant milestone in the evolution of macrolide antibiotics.

The regulatory journey in the United States, overseen by the Food and Drug Administration (FDA), reflects a strategic expansion of its clinical applications. The original brand name, Biaxin, manufactured by Abbott Laboratories (now AbbVie), received its initial approval for the immediate-release tablet formulation on October 31, 1991.[22] This was followed by the approval of an oral suspension on December 23, 1993, to facilitate pediatric dosing.[22]

A key development in the drug's lifecycle was the approval of an extended-release formulation, Biaxin XL, on October 20, 2000.[23] This once-daily formulation was designed to improve patient adherence and convenience compared to the twice-daily regimen of the immediate-release version, a common strategy to maintain market relevance in the face of impending generic competition. Biaxin XL was initially approved for acute bacterial exacerbation of chronic bronchitis and acute maxillary sinusitis.[23] Its indications were further expanded on August 6, 2001, to include community-acquired pneumonia (CAP).[24] The approval pathway demonstrates a typical pharmaceutical product lifecycle, beginning with establishing a core market in common infections, expanding into more specialized and high-need indications like MAC and

H. pylori combination therapy, and finally innovating on the formulation to enhance patient convenience and extend the product's commercial viability.[22]

Today, clarithromycin is widely available as a generic medication from numerous manufacturers under various Abbreviated New Drug Applications (ANDAs).[25] Its global importance is underscored by its inclusion on the World Health Organization's List of Essential Medicines, which recognizes it as one of the safest and most effective medicines needed in a health system.[6]

2.0 Molecular Pharmacology and Mechanism of Action

2.1 Primary Antibacterial Mechanism: Inhibition of Protein Synthesis

2.1.1 Binding to the 50S Ribosomal Subunit

The primary mechanism by which clarithromycin exerts its antibacterial effect is through the inhibition of protein synthesis in susceptible bacteria, a characteristic shared by all macrolide antibiotics.[1] The process begins with the drug's penetration of the bacterial cell wall. Once inside the cell, clarithromycin reversibly binds with high affinity to a specific site on the bacterial ribosome.[1]

The molecular target is Domain V of the 23S ribosomal RNA (rRNA), a critical structural and functional component of the 50S large ribosomal subunit.[1] In some organisms, such as

Shigella flexneri, the target has been more specifically identified as the Large ribosomal subunit protein uL10.[1] This binding event occurs within the polypeptide exit tunnel of the ribosome. By occupying this site, clarithromycin physically obstructs the passage of the nascent polypeptide chain. This leads to the inhibition of peptidyl transferase activity and blocks the translocation step of protein synthesis, where aminoacyl transfer-RNA (tRNA) moves from the A-site to the P-site of the ribosome.[1] The ultimate consequence is the premature dissociation of the incomplete peptide chain and a halt in the production of essential bacterial proteins, which prevents bacterial growth and replication.[1]

2.1.2 Bacteriostatic vs. Bactericidal Activity

Clarithromycin is predominantly classified as a bacteriostatic agent, meaning it inhibits bacterial growth and multiplication rather than directly killing the organisms.[1] This allows the host's immune system to clear the contained infection. However, this classification is not absolute. Under certain conditions, clarithromycin can exhibit bactericidal (bacteria-killing) activity.[1] This dual activity is dependent on several factors, including the drug concentration at the site of infection and the specific susceptibility of the target organism.[1] At higher concentrations, the inhibition of protein synthesis can be profound enough to be lethal to the bacteria. Documented bactericidal activity has been observed against several clinically important pathogens, including

Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, and Helicobacter pylori.[27]

2.2 Pharmacodynamics and Spectrum of Antimicrobial Activity

Clarithromycin possesses a broad spectrum of antimicrobial activity that encompasses a wide range of clinically relevant pathogens. Its in-vitro potency is generally similar to or greater than that of its parent compound, erythromycin, against organisms that are susceptible to erythromycin.[1] The spectrum includes many Gram-positive and Gram-negative aerobic bacteria, as well as atypical organisms, some anaerobes, and mycobacteria. A detailed summary of its spectrum of activity is provided in Table 2.

Table 2: Spectrum of Antimicrobial Activity of Clarithromycin

Category	Organism	Clinical Relevance/Note	Source(s)
Gram-Positive Aerobes	Staphylococcus aureus	Active against methicillin-susceptible strains (MSSA) only; not active against MRSA.	1
	Streptococcus pneumoniae	Key pathogen in respiratory tract infections.	1
	Streptococcus pyogenes (Group A)	Common cause of pharyngitis and skin infections.	1
	Streptococcus agalactiae (Group B)	In-vitro activity demonstrated.	7
	Listeria monocytogenes	In-vitro activity demonstrated.	27
	Viridans group streptococci	In-vitro activity demonstrated.	1
Gram-Negative Aerobes	Haemophilus influenzae	Common respiratory pathogen. Efficacy enhanced by the active 14-OH metabolite.	1
	Haemophilus parainfluenzae	Respiratory pathogen.	7
	Moraxella catarrhalis	Common cause of sinusitis, otitis media, and bronchitis exacerbations.	1
	Helicobacter pylori	Primary target in peptic ulcer disease eradication therapy.	1
	Legionella pneumophila	Causative agent of Legionnaires' disease.	7
	Bordetella pertussis	Causative agent of whooping cough.	7
	Neisseria gonorrhoeae	In-vitro activity demonstrated.	27
	Campylobacter jejuni	In-vitro activity demonstrated.	27
Mycobacteria	Mycobacterium avium complex (MAC)	Critical indication for treatment and prophylaxis in immunocompromised patients.	2
	Mycobacterium leprae	Causative agent of leprosy.	27
Atypical Organisms	Mycoplasma pneumoniae	Common cause of atypical pneumonia.	7
	Chlamydia pneumoniae (TWAR)	Common cause of atypical pneumonia.	1
	Chlamydia trachomatis	In-vitro activity demonstrated.	27
	Ureaplasma urealyticum	In-vitro activity demonstrated.	27
Other Organisms	Toxoplasma gondii	Used in combination therapy for toxoplasmic encephalitis in HIV patients.	1
	Borrelia burgdorferi	Causative agent of Lyme disease; used as a second-line agent.	1
	Bartonella species	Causative agent of cat scratch disease and other forms of bartonellosis.	1
Anaerobes	Clostridium perfringens	In-vitro activity demonstrated.	7
	Peptostreptococcus species	In-vitro activity demonstrated.	27
	Cutibacterium acnes (formerly Propionibacterium acnes)	In-vitro activity demonstrated.	7

2.3 Non-Antibacterial Mechanisms: Immunomodulatory and Neurological Effects

Beyond its direct action on bacteria, clarithromycin possesses a range of non-antibiotic properties that are of increasing clinical and investigational interest. These effects suggest that the drug's therapeutic identity may be broader than that of a conventional anti-infective agent.

2.3.1 Cytokine Modulation and Anti-Inflammatory Properties

Clarithromycin is recognized for its significant immunomodulatory effects, a property characteristic of 14- and 15-membered macrolides but not 16-membered ones.[10] These actions are independent of its ability to inhibit bacterial protein synthesis and involve direct modulation of the host's immune response. The drug can suppress the production and gene expression of several key pro-inflammatory cytokines, including Interleukin-1β (IL-1β), IL-2, IL-5, IL-6, and Tumor Necrosis Factor-alpha (TNF-α).[5] For instance, by suppressing IL-1β, clarithromycin can indirectly reduce the production of IL-6, a critical growth factor for multiple myeloma cells.[10] Conversely, it has been shown to induce the production of the anti-inflammatory cytokine IL-4, which can inhibit IL-6 synthesis and reduce plasma cell growth.[10]

These anti-inflammatory actions form the basis for its successful use in chronic inflammatory pulmonary diseases such as diffuse panbronchiolitis and cystic fibrosis, where it can reduce neutrophil-driven inflammation and improve clinical outcomes.[29] This capacity to temper excessive host inflammatory responses has also led to its investigation as an adjunctive therapy in severe acute infections, including community-acquired pneumonia and COVID-19, with the goal of preventing progression to severe respiratory failure.[11] Furthermore, these pleiotropic effects are being explored in oncology, where clarithromycin is under investigation as an add-on therapy for hematologic malignancies like multiple myeloma, potentially through mechanisms such as autophagy inhibition and suppression of myeloma growth factors.[10]

2.3.2 Investigational Effects on GABA-A Receptors

A distinct and more recently discovered non-antibiotic mechanism of clarithromycin involves its interaction with the central nervous system. Emerging research has identified clarithromycin as a negative allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor.[7] GABA is the primary inhibitory neurotransmitter in the brain, and its action at the GABA-A receptor promotes sleep and sedation. By negatively modulating this receptor, clarithromycin is hypothesized to reduce GABAergic signaling, thereby producing a wakefulness-promoting (somnolytic) effect.[7]

This novel neurological mechanism is completely unrelated to its antibacterial function and has opened a new avenue of clinical investigation. Clarithromycin is being actively researched as a potential treatment for central disorders of hypersomnolence, such as idiopathic hypersomnia (IH) and narcolepsy type 2.[7] Clinical trials have demonstrated that clarithromycin can produce clinically meaningful improvements in subjective sleepiness in patients with these conditions, and the American Academy of Sleep Medicine has issued a conditional recommendation for its use in patients who are refractory to standard therapies.[7] This potential "repurposing" of an established antibiotic for a primary neurological disorder highlights a paradigm shift in understanding the drug's full therapeutic potential.

3.0 Comprehensive Pharmacokinetic Profile

The clinical efficacy and safety of clarithromycin are governed by its pharmacokinetic properties—the processes of absorption, distribution, metabolism, and excretion (ADME). Its profile represents a significant improvement over its predecessor, erythromycin.

3.1 Absorption and Bioavailability

Following oral administration, clarithromycin is rapidly and effectively absorbed from the gastrointestinal tract.[1] A key chemical advantage is its stability in the presence of gastric acid, which allows for reliable oral absorption without the need for protective enteric coatings and contributes to its improved gastrointestinal tolerability compared to erythromycin.[2]

The absolute bioavailability of a 250 mg immediate-release clarithromycin tablet is approximately 50%, with the remaining fraction undergoing extensive first-pass metabolism.[4] The presence of food has a modest effect on the absorption of the immediate-release formulation. Food can slightly delay the onset of absorption, increasing the time to reach peak plasma concentration (Tmax) from approximately 2 hours to 2.5 hours. It may also increase the peak plasma concentration (Cmax) by about 24%, but it does not significantly alter the total extent of drug absorption, as measured by the area under the concentration-time curve (AUC).[4] In contrast, the administration instructions for the extended-release (XL) tablets specify that they should be taken with food to ensure proper absorption.[8]

3.2 Distribution

Once absorbed into the systemic circulation, clarithromycin distributes readily into body tissues and fluids.[4] In plasma, it is approximately 70% bound to proteins.[1] A defining characteristic of clarithromycin, and macrolides in general, is its excellent tissue penetration, leading to concentrations in tissues that are substantially higher than those in the serum.[4]

The drug is actively transported into phagocytic cells, such as neutrophils and macrophages, which then migrate to sites of infection. During active phagocytosis, large concentrations of clarithromycin are released, effectively delivering the antibiotic directly to the location of the pathogens.[7] Tissue concentrations can be more than 10 times higher than concurrent plasma concentrations, with the highest levels observed in the liver, lung tissue (including epithelial lining fluid and alveolar macrophages), and stool.[5] This high degree of tissue penetration is fundamental to its efficacy in treating respiratory and soft-tissue infections.[39] While total drug concentrations in tissues are high, studies using in-vivo microdialysis have shown that the concentration of free, unbound drug in the interstitial fluid of subcutaneous and skeletal muscle tissue is lower than in plasma, with tissue-to-plasma free AUC ratios of approximately 0.4.[39]

3.3 Metabolism: The Role of CYP3A4 and the Active Metabolite (14-hydroxyclarithromycin)

Clarithromycin undergoes rapid and extensive first-pass metabolism in the liver following oral absorption.[7] The primary pathway for its metabolism is mediated by the cytochrome P450 3A4 (CYP3A4) isoenzyme, which is responsible for hydroxylation and N-demethylation reactions.[1] This metabolic pathway is of profound clinical importance because clarithromycin is not only a substrate of CYP3A4 but also a potent inhibitor of the enzyme.[1] This dual role as a substrate and inhibitor is the mechanistic basis for its numerous and clinically significant drug-drug interactions.

The principal metabolite formed is 14-(R)-hydroxyclarithromycin (14-OH clarithromycin).[1] This metabolite is not an inactive byproduct; it is microbiologically active and works synergistically with the parent compound to enhance its overall antibacterial effect.[1] The activity of the 14-OH metabolite varies depending on the target pathogen. For most organisms, it is less potent than the parent drug. However, it exhibits twofold greater activity than clarithromycin against

Haemophilus influenzae, a common respiratory pathogen.[5] This enhanced activity of the metabolite is a key contributor to clarithromycin's clinical efficacy in treating infections caused by this organism. Other, less significant metabolites, such as N-desmethylclarithromycin, are also formed.[7]

3.4 Elimination and Half-Life

Clarithromycin and its metabolites are eliminated from the body through both renal and fecal routes.[4] For the immediate-release tablet formulation, approximately 20% to 30% of an administered dose is excreted unchanged in the urine. This fraction is higher, at around 40%, for the oral suspension formulation.[4] The active 14-OH metabolite accounts for an additional 10% to 15% of the dose recovered in the urine.[4] The remainder of the drug is eliminated through non-renal pathways, primarily in the feces after hepatic metabolism and biliary excretion.

The pharmacokinetics of clarithromycin are slightly non-linear, which is reflected in its dose-dependent elimination half-life.[4]

• Following a 250 mg dose administered every 12 hours, the elimination half-life of the parent drug is approximately 3 to 4 hours, while the half-life of the 14-OH metabolite is 5 to 6 hours.[4]
• When the dose is increased to 500 mg every 8 to 12 hours, the half-life of clarithromycin extends to 5 to 7 hours, and that of the 14-OH metabolite increases to 7 to 9 hours.[4]

Steady-state plasma concentrations of both the parent drug and its active metabolite are typically achieved within 3 days of initiating a consistent dosing regimen.[4] A summary of these key pharmacokinetic parameters is presented in Table 3.

Table 3: Summary of Pharmacokinetic Parameters for Clarithromycin and its Active Metabolite

Parameter	Clarithromycin (Parent Drug)	14-OH Clarithromycin (Active Metabolite)	Source(s)
Oral Bioavailability	~50%	N/A	7
Tmax (Immediate-Release)	~2–2.5 hours	N/A	4
Plasma Protein Binding	~70%	N/A	1
Half-life (t1/2​) at 250 mg q12h	3–4 hours	5–6 hours	4
Half-life (t1/2​) at 500 mg q8-12h	5–7 hours	7–9 hours	4
Primary Metabolism	Hepatic (CYP3A4)	N/A	1
Primary Route of Elimination	Renal and Fecal	Renal	4

4.0 Clinical Applications and Therapeutic Indications

The clinical use of clarithromycin is guided by its broad antimicrobial spectrum and favorable pharmacokinetic profile. It is indicated for a range of infections, with specific recommendations for dosing and duration varying by condition, patient population, and formulation. A guiding principle for its prescription is to reserve its use for infections that are proven or strongly suspected to be caused by susceptible bacteria, in order to mitigate the development of antimicrobial resistance.[38]

4.1 FDA-Approved Indications

Clarithromycin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate infections caused by designated susceptible microorganisms.[8]

4.1.1 Respiratory Tract Infections

This category represents a primary area of use for clarithromycin.

• Acute Maxillary Sinusitis: Indicated for infections caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.[1]
• Acute Bacterial Exacerbation of Chronic Bronchitis: For infections caused by H. influenzae, Haemophilus parainfluenzae, M. catarrhalis, or S. pneumoniae.[1]
• Community-Acquired Pneumonia (CAP): Approved for CAP caused by typical pathogens such as H. influenzae and S. pneumoniae, as well as atypical pathogens like Mycoplasma pneumoniae and Chlamydophila pneumoniae (TWAR).[1]
• Pharyngitis/Tonsillitis: For infections caused by Streptococcus pyogenes. It serves as a valuable alternative for patients with a history of type I hypersensitivity to penicillin.[1]
• Acute Otitis Media (Pediatric): For ear infections in children caused by H. influenzae, M. catarrhalis, or S. pneumoniae.[1]

4.1.2 Uncomplicated Skin and Skin Structure Infections

Clarithromycin is indicated for the treatment of uncomplicated skin and soft tissue infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.[1]

4.1.3 Eradication of Helicobacter pylori in Peptic Ulcer Disease

A critical indication for clarithromycin is its role in multi-drug regimens for the eradication of H. pylori, the bacterium responsible for most peptic ulcers.[1] To prevent the rapid development of resistance, it is always used in combination with other agents. Approved regimens include triple therapy with a proton pump inhibitor (such as omeprazole or lansoprazole) and another antibiotic (typically amoxicillin), or as part of a co-packaged triple therapy with vonoprazan and amoxicillin.[1]

4.1.4 Treatment and Prophylaxis of Mycobacterium avium Complex (MAC)

Clarithromycin is a key agent in the management of infections caused by the Mycobacterium avium complex (MAC), particularly in immunocompromised individuals such as those with advanced HIV infection.[1] It is FDA-approved for both the treatment of active, disseminated MAC disease and for primary prophylaxis to prevent the initial occurrence of infection in high-risk patients (e.g., those with CD4 counts below 50 cells/mm³).[2]

4.2 Off-Label and Investigational Uses

In addition to its approved indications, clarithromycin is used for several other conditions based on clinical evidence and guideline recommendations.

4.2.1 Management of Other Infections

• Pertussis (Whooping Cough): Recommended by the Centers for Disease Control and Prevention (CDC) as a preferred macrolide for the treatment of pertussis.[1]
• Lyme Disease: Utilized as a second-line or alternative agent for the treatment of early Lyme disease, particularly in patients who cannot take first-line therapies like doxycycline.[1]
• Bartonellosis: Employed for infections caused by Bartonella species, including cat scratch disease.[1]
• Toxoplasma gondii Encephalitis: Used in combination with pyrimethamine as an alternative regimen for treating this opportunistic infection in HIV-infected patients.[1]
• Cryptosporidiosis: May be used to decrease the incidence of this protozoal infection that causes diarrhea.[1]
• Bacterial Endocarditis Prophylaxis: Recommended as an alternative to penicillin for prophylaxis against α-hemolytic (viridans group) streptococcal endocarditis in at-risk patients undergoing certain dental or respiratory tract procedures.[1]

4.2.2 Emerging Therapeutic Areas

• Idiopathic Hypersomnia (IH): Clarithromycin has been researched as a potential treatment for IH and other central hypersomnia syndromes. This use is based on its proposed mechanism as a negative allosteric modulator of the GABA-A receptor, which may promote wakefulness.[7] Although evidence is still limited, the American Academy of Sleep Medicine has issued a conditional recommendation for its use in patients who have not responded to other therapies.[7]
• Oncology: The immunomodulatory and potential anti-proliferative effects of clarithromycin have led to its investigation as an adjunctive therapy for certain cancers. It has shown some efficacy in treating hematologic malignancies such as multiple myeloma and mucosa-associated lymphoid tissue (MALT) lymphoma.[10] Active NCI-supported clinical trials are exploring its use in combination with targeted agents like Selinexor for multiple myeloma.[12]
• COVID-19: During the COVID-19 pandemic, clinical trials were initiated to evaluate whether the anti-inflammatory properties of clarithromycin could attenuate the hyperinflammatory response (cytokine storm) and prevent progression to severe respiratory failure in infected patients.[11]

4.3 Dosage, Administration, and Available Formulations

Clarithromycin is available in several oral formulations to accommodate different patient needs and clinical scenarios.

• Available Formulations:
• Immediate-Release (IR) Tablets: Strengths of 250 mg and 500 mg.[38]
• Extended-Release (XL) Tablets: Strength of 500 mg, typically administered as a 1000 mg (two tablets) once-daily dose.[41]
• Granules for Oral Suspension: Reconstituted to provide concentrations of 125 mg/5 mL and 250 mg/5 mL, primarily for pediatric use or for adults who cannot swallow tablets.[38]
• Administration:
• Immediate-release tablets and the oral suspension may be administered with or without food.[1] Taking with food or milk may mitigate gastrointestinal upset.[47]
• Extended-release tablets must be taken with food and must be swallowed whole. They should not be crushed, broken, or chewed, as this would destroy the extended-release mechanism.[8]

4.3.1 Adult and Pediatric Dosing Regimens

Dosing for clarithromycin is highly dependent on the indication, patient age, severity of infection, and the formulation used. A summary of common FDA-approved dosing regimens is provided in Table 4.

Table 4: FDA-Approved Dosing Regimens for Clarithromycin by Indication

Indication	Patient Population	Formulation	Dose	Frequency	Duration	Source(s)
Community-Acquired Pneumonia	Adult	IR Tablet	250 mg	Every 12 hours	7–14 days	8
	Adult	XL Tablet	1000 mg (2 x 500 mg)	Once daily	7 days	41
	Pediatric (≥6 mos)	Suspension	7.5 mg/kg	Every 12 hours	10 days	8
Acute Maxillary Sinusitis	Adult	IR Tablet	500 mg	Every 12 hours	14 days	42
	Adult	XL Tablet	1000 mg (2 x 500 mg)	Once daily	14 days	41
Acute Exacerbation of Chronic Bronchitis	Adult	IR Tablet	250–500 mg	Every 12 hours	7–14 days	42
	Adult	XL Tablet	1000 mg (2 x 500 mg)	Once daily	7 days	41
Pharyngitis / Tonsillitis	Adult	IR Tablet	250 mg	Every 12 hours	10 days	42
Uncomplicated Skin Infection	Adult	IR Tablet	250 mg	Every 12 hours	7–14 days	42
H. pylori Eradication	Adult	IR Tablet	500 mg	Every 8–12 hours (regimen dependent)	10–14 days	8
MAC Prophylaxis / Treatment	Adult	IR Tablet	500 mg	Twice daily	Ongoing	8
	Pediatric (≥20 mos)	Suspension	7.5 mg/kg (up to 500 mg)	Twice daily	Ongoing	8
Acute Otitis Media	Pediatric (≥6 mos)	Suspension	7.5 mg/kg	Every 12 hours	10 days	8

4.3.2 Dosage Adjustments in Renal Impairment

Clarithromycin clearance is reduced in patients with impaired renal function.

• For patients with severe renal impairment (Creatinine Clearance [CrCl] < 30 mL/min), the total daily dose of clarithromycin should be reduced by 50%.[41]
• Specific caution and further dose reductions are required for patients with moderate (CrCl 30 to 60 mL/min) or severe renal impairment who are concomitantly receiving strong CYP3A4 inhibitors such as the HIV protease inhibitors atazanavir or ritonavir. In these cases, the clarithromycin dose should be reduced by 50% for moderate impairment and 75% for severe impairment.[41]
• No dosage adjustment is generally recommended for patients with hepatic impairment, provided their renal function is normal.[14] Hemodialysis and peritoneal dialysis do not significantly affect serum levels of clarithromycin.[27]

5.0 Safety, Tolerability, and Risk Management

The clinical utility of clarithromycin is balanced by a well-defined safety profile that includes a range of adverse effects, significant drug-drug interactions, and a major cardiovascular warning. A thorough understanding of these risks is essential for its safe and effective use.

5.1 Common and Serious Adverse Drug Reactions

• Gastrointestinal Effects: The most frequently reported adverse reactions are gastrointestinal in nature. These include abdominal pain (3%), diarrhea (3%), nausea (3%), vomiting (6%), and dysgeusia, an abnormal or metallic taste in the mouth (3%).[1] While often mild and transient, these effects can be bothersome and may impact patient adherence.[48]
• Central Nervous System (CNS) Effects: Common CNS side effects include headache and dizziness.[7] Less frequently, more severe neuropsychiatric events have been reported, such as insomnia, anxiety, vivid dreams, nightmares, panic attacks, delirium, and mania.[7] Ototoxicity, manifesting as transient hearing loss, has been observed, particularly with high doses.[1]
• Hepatotoxicity: Clarithromycin is associated with a risk of liver injury. This can range from asymptomatic elevations in liver function tests to severe, clinically apparent hepatocellular and/or cholestatic hepatitis, with or without jaundice.[1] While this hepatic dysfunction is typically reversible upon discontinuation of the drug, rare cases of fatal hepatic failure have been reported.[1] Patients should be advised to report symptoms of liver problems, such as dark urine, pale stools, jaundice, pruritus, or tender abdomen.[48]
• Infectious Complications: As with nearly all antibacterial agents, clarithromycin use can disrupt the normal gut flora, leading to an overgrowth of Clostridioides difficile. This can result in C. difficile-associated diarrhea (CDAD), which may range in severity from mild diarrhea to life-threatening pseudomembranous colitis.[1] Fungal superinfections, such as oral or vaginal candidiasis, can also occur due to the elimination of natural bacterial competitors.[6]
• Musculoskeletal Effects: Clarithromycin has been reported to cause an exacerbation of the symptoms of myasthenia gravis, a chronic autoimmune neuromuscular disease characterized by skeletal muscle weakness.[8]
• Severe Hypersensitivity Reactions: Although rare, severe and potentially fatal acute hypersensitivity reactions can occur. These include anaphylaxis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If such a reaction occurs, clarithromycin must be discontinued immediately and appropriate therapy instituted.[1]

5.2 Cardiovascular Risk Profile

The cardiovascular effects of clarithromycin represent one of its most significant safety concerns.

5.2.1 QT Interval Prolongation and Arrhythmias

Clarithromycin is known to prolong the QT interval on an electrocardiogram (ECG), a condition that affects cardiac repolarization.[7] This effect increases the risk of developing life-threatening ventricular arrhythmias, most notably torsades de pointes, which can lead to syncope and sudden cardiac death.[7] The risk is elevated in patients with underlying risk factors, including:

• Congenital or acquired long QT syndrome.[7]
• Uncorrected electrolyte imbalances, particularly hypokalemia or hypomagnesemia.[8]
• Significant bradycardia (slow heart rate).[8]
• Concomitant use of other medications known to prolong the QT interval.[7]

5.2.2 Special Report: The FDA Safety Communication on Long-Term Cardiovascular Mortality

In February 2018, the U.S. FDA issued a pivotal drug safety communication that fundamentally altered the risk assessment for clarithromycin, especially in patients with cardiovascular disease.[7] This warning was based on a 10-year follow-up of the CLARICOR trial, a large, randomized, placebo-controlled study.[17]

• Key Finding: The trial unexpectedly found a statistically significant increase in all-cause mortality among patients with stable coronary heart disease who had received a short, two-week course of clarithromycin compared to those who received a placebo.[7] Critically, this increased risk of death was not immediate but became apparent only after patients had been followed for one year or longer.[16]
• FDA Action and Recommendation: In response to this evidence, the FDA added a new warning to the clarithromycin drug labels detailing this increased risk.[16] The agency strongly advises caution and recommends that "healthcare professionals should be aware of these significant risks and weigh the benefits and risks of clarithromycin before prescribing it to any patient, particularly in patients with heart disease and even for short periods, and consider using other available antibiotics".[16]
• Mechanism and Evidence: The biological mechanism for this delayed mortality effect remains unknown.[16] While several observational studies have investigated this association with conflicting results, the FDA concluded that the prospective, controlled data from the CLARICOR trial provides the strongest evidence of this risk.[7] Clarithromycin is not approved for the treatment of heart disease.[17]

5.3 Contraindications and High-Risk Populations

Based on its safety profile, clarithromycin is contraindicated or requires significant caution in several patient populations.

• Absolute Contraindications:
• Patients with a known hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.[14]
• Patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin.[8]
• Concomitant administration with cisapride, pimozide, astemizole, or terfenadine, due to the risk of QT prolongation and fatal cardiac arrhythmias.[14]
• Concomitant administration with ergotamine or dihydroergotamine, due to the risk of acute ergot toxicity (severe peripheral vasospasm and dysesthesia).[14]
• Concomitant administration with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4, specifically lovastatin and simvastatin, due to an increased risk of myopathy, including rhabdomyolysis.[49]
• Concomitant administration with lomitapide, due to the potential for markedly increased transaminases.[49]
• Concomitant administration with lurasidone.[49]
• Concomitant administration with colchicine in patients with renal or hepatic impairment.[8]
• High-Risk Populations (Use with Caution):
• Patients with coronary artery disease, per the FDA's long-term mortality warning.[9]
• Patients with risk factors for QT prolongation.[47]
• Patients with severe renal impairment (CrCl < 30 mL/min), who require dose adjustments.[8]
• Patients with myasthenia gravis, due to risk of symptom exacerbation.[8]
• Pregnancy: Clarithromycin should be avoided during pregnancy unless there are no suitable alternative therapies. Animal studies have shown adverse effects on embryo-fetal development, including cardiovascular defects and fetal growth retardation.[2]
• Breastfeeding: Clarithromycin passes into breast milk. A decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.[42]

5.4 Drug-Drug Interactions: A Clinical Perspective

Clarithromycin is involved in over 725 documented drug interactions, with 281 classified as major, meaning the risk of the interaction generally outweighs the benefit.[55]

5.4.1 Mechanism of Interaction

The vast majority of clinically significant interactions are due to clarithromycin's potent inhibition of the hepatic microsomal enzyme CYP3A4 and the drug efflux transporter P-glycoprotein (P-gp).[1] By inhibiting these pathways, clarithromycin impairs the metabolism and clearance of numerous co-administered drugs that are substrates of CYP3A4 or P-gp. This leads to elevated plasma concentrations of the interacting drug, potentially resulting in toxicity.

5.4.2 Clinically Critical Interactions

A summary of the most critical drug interactions is provided in Table 5.

Table 5: Clinically Significant Drug-Drug Interactions with Clarithromycin

Interacting Drug Class	Specific Examples	Mechanism of Interaction	Clinical Implication / Consequence	Management Recommendation	Source(s)
HMG-CoA Reductase Inhibitors (Statins)	Simvastatin, Lovastatin, Atorvastatin	Potent inhibition of CYP3A4-mediated statin metabolism.	Markedly increased statin plasma concentrations, leading to a high risk of myopathy and potentially fatal rhabdomyolysis.	Contraindicated with simvastatin and lovastatin. Avoid or use with extreme caution and lowest possible dose for atorvastatin. Withhold statin during the course of clarithromycin therapy. Consider switching to a non-CYP3A4 metabolized statin (e.g., pravastatin, rosuvastatin).	49
Oral Anticoagulants	Warfarin, Rivaroxaban, Apixaban, Dabigatran	Inhibition of CYP3A4 and/or P-gp decreases anticoagulant clearance.	Enhanced anticoagulant effect. For warfarin, this leads to an increased INR. For all, there is a significantly increased risk of major, potentially life-threatening hemorrhage.	Avoid combination if possible. If co-administration is necessary, perform close monitoring of INR (for warfarin) or for clinical signs of bleeding (for DOACs). Dose reduction of the anticoagulant may be required.	14
Calcium Channel Blockers (CCBs)	Amlodipine, Nifedipine, Diltiazem, Verapamil	Inhibition of CYP3A4-mediated CCB metabolism.	Increased CCB plasma concentrations, leading to excessive vasodilation, hypotension, and a documented increased risk of hospitalization for acute kidney injury (secondary to renal hypoperfusion) and all-cause mortality, particularly in older adults.	Avoid combination whenever possible. If unavoidable, monitor blood pressure and renal function closely. Consider using an alternative, non-interacting antibiotic (e.g., azithromycin).	48
QT-Prolonging Agents	Amiodarone, Quinidine, Sotalol, Pimozide, Disopyramide	Additive pharmacodynamic effect on cardiac repolarization (QT interval prolongation).	Substantially increased risk of life-threatening ventricular arrhythmias, including torsades de pointes.	Contraindicated with pimozide. Avoid concomitant use with other QT-prolonging drugs whenever possible. If combination is essential, ECG monitoring is warranted.	14
Ergot Alkaloids	Ergotamine, Dihydroergotamine	Inhibition of CYP3A4-mediated metabolism.	Elevated ergot alkaloid levels, leading to acute ergot toxicity characterized by severe peripheral vasospasm, ischemia, and dysesthesia.	Contraindicated.	14
Benzodiazepines	Triazolam, Midazolam (oral)	Inhibition of CYP3A4-mediated metabolism.	Increased plasma concentrations of the benzodiazepine, leading to prolonged and enhanced sedation and respiratory depression.	Monitor for excessive sedation. Dose adjustment of the benzodiazepine may be necessary.	48
Theophylline	Theophylline	Inhibition of metabolism (mechanism less defined, may involve CYP1A2).	Increased serum theophylline levels, leading to a risk of theophylline toxicity (nausea, vomiting, seizures, arrhythmias).	Monitor serum theophylline concentrations and adjust dose as needed.	14
Colchicine	Colchicine	Inhibition of CYP3A4 and P-gp decreases colchicine clearance.	Increased risk of severe, potentially fatal colchicine toxicity, especially in patients with renal or hepatic impairment.	Contraindicated in patients with renal or hepatic impairment.	6

6.0 Antibiotic Resistance

The efficacy of any antibiotic is fundamentally threatened by the ability of bacteria to develop resistance. For clarithromycin, this is a growing concern that has already reshaped clinical practice, particularly in the treatment of Helicobacter pylori.

6.1 Molecular Mechanisms of Clarithromycin Resistance

Bacteria have evolved several mechanisms to evade the action of clarithromycin.

• Target Site Modification: This is the most prevalent and clinically significant mechanism of resistance.[66] It involves alterations to the drug's binding site on the bacterial ribosome, which reduces the affinity of clarithromycin and renders it ineffective.
• The specific alterations are point mutations within the peptidyl-transferase region of Domain V of the 23S rRNA gene.[66]
• In H. pylori, three specific point mutations account for over 90% of clarithromycin-resistant strains: an adenine-to-guanine substitution at position 2143 (A2143G), and an adenine-to-guanine or adenine-to-cytosine substitution at position 2142 (A2142G or A2142C).[66]
• Efflux Pumps: Some bacteria possess membrane-bound protein pumps that can actively transport clarithromycin out of the cell before it can reach its ribosomal target. This mechanism prevents the drug from accumulating to effective intracellular concentrations.[66]
• Ribosomal Methylation: Post-transcriptional methylation of specific nucleotides within the 23S rRNA binding site can also prevent macrolide binding. This mechanism, mediated by erm (erythromycin ribosome methylation) genes, is a common form of resistance in Gram-positive bacteria and is now being investigated as a potential mechanism in H. pylori.[66]
• Novel Mutations: Advances in whole-genome sequencing are revealing new, potential mechanisms of resistance. In H. pylori, novel mutations have been identified in genes encoding for a sulfite exporter (TauE/SafE family protein) and a DUF874 family protein, which may be linked to reduced susceptibility, though their exact roles are still under investigation.[66]

6.2 Clinical Implications and Management of Resistance

The rise of clarithromycin resistance has profound implications for its clinical use.

6.2.1 The Challenge of Clarithromycin-Resistant H. pylori

The increasing prevalence of clarithromycin resistance is now recognized as the single most important factor contributing to the failure of H. pylori eradication therapies.[66] The impact is dramatic: while standard clarithromycin-based triple therapy can achieve eradication rates of nearly 90% against susceptible strains, its efficacy plummets to as low as 18% against resistant strains.[69]

Resistance rates are not uniform and vary significantly by geographic region, but the global trend is one of a steady and alarming increase. In many parts of the world, including regions of Europe, Asia, and North America, the prevalence of primary clarithromycin resistance now exceeds the 15% threshold.[66] This threshold is a critical benchmark used in major clinical guidelines; once local resistance rates surpass this level, standard clarithromycin-based triple therapy is no longer recommended as a reliable first-line empiric treatment.[66] In recognition of this growing threat, the World Health Organization (WHO) has included clarithromycin-resistant

H. pylori on its priority list of pathogens for which new antibiotics are urgently needed.[66]

6.2.2 Evolving Treatment Guidelines and Stewardship

The failure of what was once a "gold standard" therapy has necessitated a complete overhaul of clinical practice guidelines for H. pylori infection. This evolution serves as a powerful case study in the real-world impact of antibiotic resistance.

• Shift Away from Empiric Clarithromycin: The 2024 American College of Gastroenterology (ACG) guidelines represent a significant shift. Due to high and rising resistance rates in the United States (estimated at over 30%), the guidelines now strongly recommend against the empiric use of clarithromycin-containing regimens without prior antibiotic susceptibility testing.[71]
• Recommended First-Line Therapy: In regions with high clarithromycin resistance, or when susceptibility is unknown, the preferred first-line regimen is now a 14-day course of bismuth quadruple therapy (BQT), which consists of a proton pump inhibitor, bismuth, tetracycline, and metronidazole.[69] Other recommended alternatives include 14-day concomitant therapy (a PPI, clarithromycin, amoxicillin, and metronidazole given together) or novel regimens utilizing the potassium-competitive acid blocker vonoprazan.[69] The transition from a simple, well-tolerated triple therapy to these more complex, multi-drug, and often less-tolerated quadruple therapies is a direct consequence of resistance.
• Salvage Therapy: For patients in whom a first-line therapy fails, salvage regimens should avoid any antibiotics that were used previously. If a clarithromycin-containing regimen was used first, BQT or a levofloxacin-based regimen are preferred salvage options.[70] Conversely, if BQT was used first, a clarithromycin- or levofloxacin-based regimen could be considered, ideally guided by susceptibility testing.[70]
• Resistance in Other Pathogens: While the focus has been on H. pylori, resistance is also a concern for other pathogens. CDC guidelines for treating Group A Streptococcal pharyngitis note that while clarithromycin remains an option for penicillin-allergic patients, resistance among GAS isolates is increasingly common.[73]

7.0 Chemical Synthesis and Manufacturing

7.1 Overview of the Semi-Synthetic Pathway from Erythromycin A

Clarithromycin is not a naturally occurring compound; it is a semi-synthetic macrolide produced through the chemical modification of Erythromycin A, which is itself a product of bacterial fermentation.[5] The defining synthetic step is the selective methylation of the hydroxyl group at the 6-position of the erythromycin lactone ring, resulting in the chemical entity 6-O-methylerythromycin.[2]

This targeted methylation is structurally and functionally crucial. In the acidic environment of the stomach, the 6-OH group of erythromycin can participate in an intramolecular reaction with the C9-keto group to form an inactive 6,9-hemiketal and subsequently a 6,9;9,12-spiroketal. This degradation pathway is responsible for erythromycin's acid instability and is a major contributor to its gastrointestinal side effects. By methylating the 6-OH group, this internal reaction is blocked, rendering clarithromycin stable in gastric acid and thereby improving its oral bioavailability and tolerability.[5]

The primary challenge in the industrial synthesis of clarithromycin is achieving this methylation with high regioselectivity. The erythromycin molecule contains several other hydroxyl groups (e.g., at the C11, C12, and 4" positions) that are also susceptible to methylation. Non-selective methylation would lead to the formation of multiple undesired by-products, complicating purification and reducing the overall yield of the final product.[76]

7.2 Key Manufacturing Processes

To address the challenge of selective methylation, modern manufacturing processes employ a multi-step strategy of protection, methylation, and deprotection, as detailed in various patents.[75] A representative synthetic route includes the following key stages:

1. Oxime Formation: The synthesis typically begins with the reaction of Erythromycin A with hydroxylamine hydrochloride. This converts the C9-keto group into a 9-oxime functional group. This step serves to protect the ketone from participating in undesired side reactions during subsequent steps.[75]
2. Protection of Hydroxyl Groups: The remaining reactive hydroxyl groups, particularly the 2'-OH and 4"-OH groups on the sugar moieties, must be temporarily protected. This is commonly achieved using silylating agents such as hexamethyldisilazane (HMDS) or trimethylchlorosilane (TMS), which convert the hydroxyls into bulky silyl ethers.[75] The 9-oxime group may also be further protected with an agent like 2-methoxypropene.[75]
3. Selective 6-OH Methylation: With all other reactive sites blocked, the fully protected erythromycin derivative is subjected to the key methylation step. The molecule is treated with a methylating agent, such as methyl iodide, in the presence of a strong base like potassium hydroxide. Under these conditions, the only accessible hydroxyl group is at the C-6 position, which is selectively methylated.[75]
4. Deprotection: In the final stage, all the protecting groups are removed to yield clarithromycin. This is typically accomplished via acid hydrolysis, for example, by treatment with formic acid followed by a reducing agent like sodium metabisulphite to convert the oxime back to the free drug.[75]

Various patents describe optimizations of this general pathway, including the use of different protecting groups, solvent systems, and "one-pot" procedures designed to improve efficiency, increase overall yield, and reduce the generation of impurities and environmental waste.[75]

7.3 Global Suppliers and Brand Names

The original developer and marketer of clarithromycin was Abbott Laboratories (which later spun off its pharmaceutical division into AbbVie), under the well-known brand name Biaxin.[22] Following the expiration of its patents, the market has opened to a vast number of generic manufacturers worldwide.

Major global producers of generic clarithromycin include large pharmaceutical companies such as AdvaCare Pharma, Apotex, Aurobindo Pharma, Mylan, Sandoz, and Teva Pharmaceuticals, as well as a multitude of manufacturers based in China, India, and Europe.[78]

Reflecting its widespread global use, clarithromycin is marketed under hundreds of different brand names across various countries. In addition to Biaxin, some of the most common international brand names include Klaricid, Klacid, and Xetinin XL.[1] The sheer number of available brands and suppliers underscores its status as a globally important and widely prescribed antibiotic.

8.0 Future Directions and Concluding Remarks

8.1 Ongoing Clinical Trials and Research Frontiers

Despite being on the market for over three decades, clarithromycin continues to be the subject of active clinical investigation, a testament to its complex pharmacology. Current research is largely focused on harnessing its non-antibacterial properties for novel therapeutic applications, moving far beyond its original role as an anti-infective.

• Immunomodulation in Sepsis and Pneumonia: A key area of research is the use of clarithromycin to modulate the host immune response in severe infections. The REACT trial (NCT06294600) is a randomized clinical trial designed to investigate whether early, biomarker-guided administration of clarithromycin can prevent the progression to sepsis in patients with community-acquired pneumonia.[34] This study builds on previous findings from trials like ACCESS, which suggested that clarithromycin can attenuate the inflammatory response.[34] This line of research represents a strategic shift from using the drug to kill bacteria to using it to control the potentially damaging hyperinflammatory response of the host.
• Neurological and Sleep Disorders: Perhaps the most novel research frontier is its application in neurology. The "Clarithromycin Mechanisms in Hypersomnia Syndromes" trial (NCT04026958) is actively recruiting participants with narcolepsy and idiopathic hypersomnia to dissect the mechanisms behind its observed wakefulness-promoting effects.[36] This study aims to correlate clinical improvements in sleepiness with changes in brain activity on fMRI, GABA-A receptor potentiation in cerebrospinal fluid, systemic inflammatory markers like TNF-α, and the composition of the gut microbiome, providing a comprehensive exploration of its potential as a neuro-modulatory agent.[36]
• Oncology: The immunomodulatory and potential anti-angiogenic properties of clarithromycin continue to be explored in cancer therapy. NCI-supported clinical trials are underway to evaluate clarithromycin in combination with other anticancer agents, such as the nuclear export inhibitor Selinexor, for the treatment of multiple myeloma.[12]
• Pharmacokinetic and Drug Interaction Studies: Research also continues to refine the understanding of its pharmacokinetic profile and interaction potential. For example, a completed clinical trial (NCT02912234) specifically evaluated the effect of clarithromycin on the pharmacokinetics of the direct oral anticoagulant apixaban, providing crucial data for managing this common and high-risk drug-drug interaction.[84]

8.2 Synthesis of Clarithromycin's Role in Modern Medicine

Clarithromycin occupies a complex and evolving position in the therapeutic armamentarium. It was introduced as a pivotal second-generation macrolide that offered clear advantages in acid stability and tolerability over erythromycin, quickly establishing itself as a workhorse antibiotic for a multitude of common infections. For decades, it has been a first-line or key alternative agent for respiratory tract infections, skin infections, and, most notably, as part of the revolutionary multi-drug regimens that made the cure of H. pylori-induced peptic ulcer disease possible.

However, the clinical landscape for clarithromycin is now defined by two formidable challenges that are progressively constraining its traditional role. The first is the relentless global rise of antibiotic resistance, which has had its most dramatic impact on the treatment of H. pylori. The drug's efficacy has been so severely eroded that what was once a gold-standard therapy is now recommended against for empiric use in many regions, a stark illustration of the consequences of antimicrobial resistance. The second challenge is its intricate safety profile, which is dominated by its potent inhibition of CYP3A4—leading to a vast and hazardous web of drug-drug interactions—and a serious FDA warning regarding an unexplained increase in long-term cardiovascular mortality in patients with heart disease.

In this context, the future of clarithromycin may lie less in its utility as a frontline antibiotic and more in the strategic exploitation of its "secondary" non-antimicrobial properties. The ongoing, high-quality research into its immunomodulatory effects in sepsis and its neuro-modulatory actions in hypersomnia could potentially redefine its place in medicine. This evolution—from a straightforward anti-infective to a complex modulator of host biology—encapsulates the dynamic and often unpredictable lifecycle of a pharmaceutical agent. The story of clarithromycin thus serves a dual purpose: it is a potent reminder of the critical need for antibiotic stewardship to preserve the efficacy of our existing anti-infectives, while also demonstrating the remarkable potential for established molecules to find new life in treating conditions far beyond their original purpose.

Works cited

1. [Clarithromycin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 21, 2025, ][https://go.drugbank.com/drugs/DB01211]
2. [Clarithromycin | C38H69NO13 | CID 84029 - PubChem, accessed July 21, 2025, ][https://pubchem.ncbi.nlm.nih.gov/compound/Clarithromycin]
3. [www.caymanchem.com, accessed July 21, 2025, ][https://www.caymanchem.com/product/19455/clarithromycin\#:\~:text\=Product%20Description,synthase%2Dderived%20semisynthetic%20macrolide%20antibiotic.\&text\=It%20is%20active%20against%20methicillin,%C2%B5g%2Fml)%2C%20S.]
4. [Biaxin (clarithromycin) Label - accessdata.fda.gov, accessed July 21, 2025, ][https://www.accessdata.fda.gov/drugsatfda\_docs/label/2009/050662s042,050698s024,050775s013lbl.pdf]
5. [Clarithromycin: overview and its current clinical utility in the treatment of respiratory tract infections, accessed July 21, 2025, ][https://www.msjonline.org/index.php/ijrms/article/download/13064/8396/58546]
6. [CLARITHROMYCIN - New Drug Approvals, accessed July 21, 2025, ][https://newdrugapprovals.org/2021/04/01/clarithromycin/]
7. [Clarithromycin - Wikipedia, accessed July 21, 2025, ][https://en.wikipedia.org/wiki/Clarithromycin]
8. [Clarithromycin (oral route) - Side effects & dosage - Mayo Clinic, accessed July 21, 2025, ][https://www.mayoclinic.org/drugs\-supplements/clarithromycin\-oral\-route/description/drg\-20067672]
9. [Clarithromycin Patient Drug Record | NIH - Clinical Info HIV.gov, accessed July 21, 2025, ][https://clinicalinfo.hiv.gov/en/drugs/clarithromycin/patient]
10. [Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma, accessed July 21, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC7498274/]
11. [Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19, accessed July 21, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC9008033/]
12. [Clinical Trials Using Clarithromycin - NCI, accessed July 21, 2025, ][https://www.cancer.gov/research/participate/clinical\-trials/intervention/clarithromycin]
13. [Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review | Journal of Antimicrobial Chemotherapy | Oxford Academic, accessed July 21, 2025, ][https://academic.oup.com/jac/article/67/3/530/796590]
14. [Clarithromycin - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 21, 2025, ][https://www.pediatriconcall.com/drugs/clarithromycin/427]
15. [Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines, accessed July 21, 2025, ][https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5414a1\.htm]
16. [FDA Drug Safety Communication: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease, accessed July 21, 2025, ][https://www.fda.gov/drugs/drug\-safety\-and\-availability/fda\-drug\-safety\-communication\-fda\-review\-finds\-additional\-data\-supports\-potential\-increased\-long]
17. [FDA review finds additional data supports the potential for increased ..., accessed July 21, 2025, ][https://www.fda.gov/media/111300/download]
18. [Definition of clarithromycin - NCI Drug Dictionary, accessed July 21, 2025, ][https://www.cancer.gov/publications/dictionaries/cancer\-drug/def/clarithromycin]
19. [Clarithromycin | CAS 81103-11-9 | SCBT - Santa Cruz Biotechnology, accessed July 21, 2025, ][https://www.scbt.com/p/clarithromycin\-81103\-11\-9]
20. [Clarithromycin = 95 HPLC 81103-11-9 - Sigma-Aldrich, accessed July 21, 2025, ][https://www.sigmaaldrich.com/US/en/product/sigma/c9742]
21. [Clarithromycin, Macrolide antibiotic (CAS 81103-11-9) (ab141202) | Abcam, accessed July 21, 2025, ][https://www.abcam.com/en\-us/products/biochemicals/clarithromycin\-macrolide\-antibiotic\-ab141202]
22. [Generic Biaxin Availability - Drugs.com, accessed July 21, 2025, ][https://www.drugs.com/availability/generic\-biaxin.html]
23. [Drug Approval Package: Biaxin XL Filmtab (Clarithromycin) NDA #50-775S1, accessed July 21, 2025, ][https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2000/50775S1\_Biaxin.cfm]
24. [FDA approves Abbott's Biaxin® XL (clarithromycin extended-release tablet)for community-acquired pneumonia | EurekAlert!, accessed July 21, 2025, ][https://www.eurekalert.org/news\-releases/473867]
25. [Clarithromycin - FDA Approval - MedPath, accessed July 21, 2025, ][https://trial.medpath.com/drug/approvals/fda/f67a31f0f784d48c]
26. [Clarithromycin. | DrugBank Online, accessed July 21, 2025, ][https://go.drugbank.com/articles/A2124]
27. [Clarithromycin 500 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc) | 7072, accessed July 21, 2025, ][https://www.medicines.org.uk/emc/product/7072/smpc]
28. [The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms - PubMed, accessed July 21, 2025, ][https://pubmed.ncbi.nlm.nih.gov/29593707/]
29. [Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? - Oxford Academic, accessed July 21, 2025, ][https://academic.oup.com/jac/article/55/1/10/777163]
30. [Clarithromycin impairs tissue-resident memory and Th17 responses to macrolide-resistant Streptococcus pneumoniae infections - PubMed Central, accessed July 21, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC8164591/]
31. [The immunomodulatory effects of macrolide antibiotics in respiratory disease - PMC, accessed July 21, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC8563091/]
32. [Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease - PubMed, accessed July 21, 2025, ][https://pubmed.ncbi.nlm.nih.gov/15203552/]
33. [Study Details | Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early, accessed July 21, 2025, ][https://www.clinicaltrials.gov/study/NCT04398004?term\=KLARICID\&rank\=5]
34. [Study Details | Clarithromycin Treatment to Prevent Sepsis ..., accessed July 21, 2025, ][https://clinicaltrials.gov/study/NCT06294600]
35. [Clarithromycin in GABA-related Hypersomnolence: A Randomized, Crossover Trial - PMC, accessed July 21, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC4732573/]
36. [Study Details | Clarithromycin Mechanisms in Hypersomnia Syndromes | ClinicalTrials.gov, accessed July 21, 2025, ][https://www.clinicaltrials.gov/study/NCT04026958?term\=Clarithromycin\&viewType\=Table\&rank\=9]
37. [Clarithromycin Mechanisms in Hypersomnia Syndromes | Clinical Research Trial Listing, accessed July 21, 2025, ][https://www.centerwatch.com/clinical\-trials/listings/NCT04026958/clarithromycin\-mechanisms\-in\-hypersomnia\-syndromes]
38. [CLARITHROMYCIN TABLETS, USP AND CLARITHROMYCIN FOR ..., accessed July 21, 2025, ][https://www.accessdata.fda.gov/drugsatfda\_docs/label/2007/065382s000lbl.pdf]
39. [Pharmacokinetics of Single- and Multiple-Dose Oral Clarithromycin in Soft Tissues Determined by Microdialysis | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed July 21, 2025, ][https://journals.asm.org/doi/10\.1128/aac.00532\-07]
40. [N-Desmethyl Clarithromycin | C37H67NO13 | CID 11072636 - PubChem, accessed July 21, 2025, ][https://pubchem.ncbi.nlm.nih.gov/compound/N\-Desmethyl\-Clarithromycin]
41. [These highlights do not include all the information needed to use CLARITHROMYCIN EXTENDED-RELEASE TABLETS safely and effectively - Clinical Info HIV.gov, accessed July 21, 2025, ][https://clinicalinfo.hiv.gov/sites/default/files/drugs/documents/99/FDA\_Label%26\_Tablet\_%28film\-coated%2C\_extended\_release%29\.pdf]
42. [SUMMARY PRODUCT CHARACTERISTICS 1. Name of drug product: 2. Qualitative and Quantitative Composition: 3. Pharmaceutical form: - Rwanda FDA, accessed July 21, 2025, ][https://rwandafda.gov.rw/wp\-content/uploads/2024/03/Clarithromycin%20tablets\_250mg\_SmPC.pdf]
43. [clarithromycin (Biaxin) - International Association of Providers of AIDS Care, accessed July 21, 2025, ][https://www.iapac.org/fact\-sheet/clarithromycin\-biaxin/]
44. [medlineplus.gov, accessed July 21, 2025, ][https://medlineplus.gov/druginfo/meds/a692005\.html\#:\~:text\=Clarithromycin%20also%20is%20used%20sometimes,or%20scratched%20by%20a%20cat)%2C]
45. [Clarithromycin: MedlinePlus Drug Information, accessed July 21, 2025, ][https://medlineplus.gov/druginfo/meds/a692005\.html]
46. [Clarithromycin (Biaxin): Uses, Side Effects, Warnings & More - GoodRx, accessed July 21, 2025, ][https://www.goodrx.com/clarithromycin/what\-is]
47. [clarithromycin 500 mg tablet - Kaiser Permanente, accessed July 21, 2025, ][https://healthy.kaiserpermanente.org/health\-wellness/drug\-encyclopedia/drug.clarithromycin\-500\-mg\-tablet.177323]
48. [Clarithromycin: Side Effects, Dosage, Uses, and More - Healthline, accessed July 21, 2025, ][https://www.healthline.com/health/drugs/clarithromycin\-oral\-tablet]
49. [Clarithromycin: Package Insert / Prescribing Information - Drugs.com, accessed July 21, 2025, ][https://www.drugs.com/pro/clarithromycin.html]
50. [www.nhs.uk, accessed July 21, 2025, ][https://www.nhs.uk/medicines/clarithromycin/side\-effects\-of\-clarithromycin/\#:\~:text\=a%20faster%20or%20irregular%20heartbeat,inflammation%20of%20the%20pancreas%20(pancreatitis)]
51. [Who can and cannot take clarithromycin - NHS, accessed July 21, 2025, ][https://www.nhs.uk/medicines/clarithromycin/who\-can\-and\-cannot\-take\-clarithromycin/]
52. [FDA Drug Safety Communication: Clarithromycin and Increased Potential Risk of Heart Problems or Death in Patients With Heart Disease - PcMED Project, accessed July 21, 2025, ][https://pcmedproject.com/id/fda\-drug\-safety\-communication\-clarithromycin\-and\-increased\-potential\-risk\-of\-heart\-problems\-or\-death\-in\-patients\-with\-heart\-disease/]
53. [FDA Warns Clarithromycin May Increase Cardiovascular Risk in Patients With CHD, accessed July 21, 2025, ][https://www.acc.org/latest\-in\-cardiology/articles/2018/02/26/10/37/fda\-warns\-clarithromycin\-may\-increase\-cardiovascular\-risk\-in\-patients\-with\-chd]
54. [What are the risks of using clarithromycin with statins, such as simvastatin (Zocor) and lovastatin (Mevacor), and how can they be mitigated? - Dr.Oracle AI, accessed July 21, 2025, ][https://www.droracle.ai/articles/147764/whats\-the\-relationship\-between\-clarithromycin\-and\-statins]
55. [Clarithromycin Interactions - Drugs.com, accessed July 21, 2025, ][https://www.drugs.com/drug\-interactions/clarithromycin.html]
56. [Drug Interactions between clarithromycin and simvastatin - Drugs.com, accessed July 21, 2025, ][https://www.drugs.com/drug\-interactions/clarithromycin\-with\-simvastatin\-685\-0\-2067\-0\.html]
57. [Drug Interactions between clarithromycin and Lipitor - Drugs.com, accessed July 21, 2025, ][https://www.drugs.com/drug\-interactions/clarithromycin\-with\-lipitor\-685\-0\-276\-128\.html]
58. [Drug Interaction Report - warfarin clarithromycin - Drugs.com, accessed July 21, 2025, ][https://www.drugs.com/interactions\-check.php?drug\_list\=685\-0,2311\-0\&professional\=1]
59. [1. Drug Interactions - GGC Medicines, accessed July 21, 2025, ][https://ggcmedicines.org.uk/media/uploads/postscript\_acute/ps\_acute\_issue\_11\_june\_2013\.pdf]
60. [Clarithromycin linked to increased haemorrhage risk in patients treated with direct oral anticoagulants - The Pharmaceutical Journal, accessed July 21, 2025, ][https://pharmaceutical\-journal.com/article/news/clarithromycin\-linked\-to\-increased\-haemorrhage\-risk\-in\-patients\-treated\-with\-direct\-oral\-anticoagulants]
61. [Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury - PubMed, accessed July 21, 2025, ][https://pubmed.ncbi.nlm.nih.gov/24346990/]
62. [Calcium-Channel Blocker Clarithromycin Drug Interactions and Kidney Injury, accessed July 21, 2025, ][https://www.clinician.com/articles/31345\-calcium\-channel\-blocker\-clarithromycin\-drug\-interactions\-and\-kidney\-injury?trendmd\-shared\=1]
63. [Calcium-Channel Blocker-Clarithromycin Drug Interactions and Acute Kidney Injury, accessed July 21, 2025, ][https://www.researchgate.net/publication/259353132\_Calcium\-Channel\_Blocker\-Clarithromycin\_Drug\_Interactions\_and\_Acute\_Kidney\_Injury]
64. [Antibiotic and Calcium-Channel Blocker a Fatal Combination - Medscape, accessed July 21, 2025, ][https://www.medscape.com/viewarticle/814306]
65. [Taking clarithromycin with other medicines and herbal supplements - NHS, accessed July 21, 2025, ][https://www.nhs.uk/medicines/clarithromycin/taking\-clarithromycin\-with\-other\-medicines\-and\-herbal\-supplements/]
66. [Exploring the Molecular Mechanisms of Macrolide Resistance in ..., accessed July 21, 2025, ][https://www.mdpi.com/2079\-6382/13/5/396]
67. [Antibiotic Susceptibility and Clarithromycin Resistance, accessed July 21, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC9952027/]
68. [pmc.ncbi.nlm.nih.gov, accessed July 21, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC9952027/\#:\~:text\=Resistance%20to%20clarithromycin%20is%20mainly,gene%20%5B7%2C9%5D.]
69. [Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy, accessed July 21, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC5505131/]
70. [ACG Clinical Guideline: Treatment of Helicobacter pylori Infection - American College of Gastroenterology, accessed July 21, 2025, ][https://acgcdn.gi.org/wp\-content/uploads/2018/04/ACG\-H.\-pylori\-Guideline\-Summary.pdf]
71. [What are the latest guideline recommendations for the treatment of Helicobacter pylori infection in the U.S.? | Drug Information Group | University of Illinois Chicago, accessed July 21, 2025, ][https://dig.pharmacy.uic.edu/faqs/2025\-2/january\-2025\-faqs/what\-are\-the\-latest\-guideline\-recommendations\-for\-the\-treatment\-of\-helicobacter\-pylori\-infection\-in\-the\-u\-s/]
72. [Updated Clinical Guidelines Outline Optimal Treatment of Helicobacter pylori Infection, accessed July 21, 2025, ][https://www.pharmacytimes.com/view/updated\-clinical\-guidelines\-outline\-optimal\-treatment\-of\-helicobacter\-pylori\-infection]
73. [Outpatient Clinical Care for Pediatric Populations | Antibiotic Prescribing and Use - CDC, accessed July 21, 2025, ][https://www.cdc.gov/antibiotic\-use/hcp/clinical\-care/pediatric\-outpatient.html]
74. [Clinical Guidance for Group A Streptococcal Pharyngitis | Group A Strep - CDC, accessed July 21, 2025, ][https://www.cdc.gov/group\-a\-strep/hcp/clinical\-guidance/strep\-throat.html]
75. [WO2006064299A1 - Industrial process of clarithromycin associated ..., accessed July 21, 2025, ][https://patents.google.com/patent/WO2006064299A1/en]
76. [Progress in synthesis of clarithromycin - ResearchGate, accessed July 21, 2025, ][https://www.researchgate.net/publication/286344720\_Progress\_in\_synthesis\_of\_clarithromycin]
77. [US8288514B2 - Method of preparing clarithromycin - Google Patents, accessed July 21, 2025, ][https://patents.google.com/patent/US8288514B2/en]
78. [Clarithromycin (International database) - Drugs.com, accessed July 21, 2025, ][https://www.drugs.com/international/clarithromycin.html]
79. [Clarithromycin Tablets – Manufacturer | AdvaCare Pharma, accessed July 21, 2025, ][https://www.advacarepharma.com/en/pharmaceuticals/clarithromycin\-tablets]
80. [Clarithromycin manufacturers and suppliers - ChemicalBook, accessed July 21, 2025, ][https://m.chemicalbook.com/Manufacturers/clarithromycin.htm]
81. [Clarithromycin: a medicine to treat bacterial infections - NHS, accessed July 21, 2025, ][https://www.nhs.uk/medicines/clarithromycin/]
82. [www.nhs.uk, accessed July 21, 2025, ][https://www.nhs.uk/medicines/clarithromycin/\#:\~:text\=Brand%20names%3A%20Klaricid%2C%20Klaricid%20XL,and%20how%20to%20take%20it.]
83. [Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes | MedPage Today, accessed July 21, 2025, ][https://www.medpagetoday.com/clinical\-trial\-finder/study/nct04026958]
84. [Study Details | Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants | ClinicalTrials.gov, accessed July 21, 2025, ][https://clinicaltrials.gov/study/NCT02912234]